Cholangiocarcinoma in liver cirrhosis

J Gastroenterol Hepatol. 2003 Mar;18(3):337-41. doi: 10.1046/j.1440-1746.2003.02977.x.

Abstract

Background and aim: Hepatocellular carcinoma (HCC) is usually associated with chronic liver diseases and liver cirrhosis, while conversely, cholangiocarcinoma (CC) usually occurs in a non-cirrhotic liver. The purpose of the present study was to evaluate CC in liver cirrhosis.

Methods: Between January 1998 and December 1999, 26 patients with CC were retrospectively reviewed. The occurrence of CC in chronic hepatitis B infection-related liver cirrhosis, portal vein thrombosis (PVT) and survival were analyzed.

Results: Twenty-six patients with CC (19 with a non-cirrhotic liver and seven with chronic hepatitis B infection-related liver cirrhosis) were included in the present study. All cases of CC in the cirrhotic group were incidentally discovered during routine screening for HCC. The mean age (+/- SD) was 58.8 +/- 14 years in the cirrhotic group and 73.2 +/- 15.9 years (P = 0.001) in the non-cirrhotic group. When compared to the cirrhotic group, the non-cirrhotic group had a higher median level of albumin (42 compared to 30 g/L, P = 0.005), bilirubin (117.5 compared to 18 micro mol/L, P = 0.01), alkaline phosphatase (291.5 compared to 100 U/L, P = 0.001) and gamma glutamyl transpeptidases (215.5 compared to 31 U/L, P = 0.001). In contrast, the cirrhotic group had a higher median prothrombin time (PT) compared to the non-cirrhotic group (18.2 compared to 12 s, P = 0.05). In the non-cirrhotic group, only one patient (5.3%) showed evidence of PVT on a computerized tomography and Doppler ultrasound, while in the cirrhotic group six patients (85.7%) had PVT (P < 0.001). The median survival period in the cirrhotic group was six months (range 2-24 months) compared to 16 months (range 6-41 months) in the non-cirrhotic group (P = 0.036).

Conclusion: CC in cirrhotic liver presented at a younger age and patients who developed CC were prone to PVT. The survival period was also shorter in comparison to that of non-cirrhotic liver patients.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Bile Duct Neoplasms / complications*
  • Bile Duct Neoplasms / mortality
  • Bile Duct Neoplasms / therapy
  • Bile Ducts, Intrahepatic / diagnostic imaging
  • Bile Ducts, Intrahepatic / pathology*
  • Biomarkers / blood
  • Biopsy
  • Chemoembolization, Therapeutic
  • Cholangiocarcinoma / complications*
  • Cholangiocarcinoma / mortality
  • Cholangiocarcinoma / therapy
  • Cholangiopancreatography, Endoscopic Retrograde
  • Female
  • Hong Kong
  • Humans
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / mortality
  • Liver Cirrhosis / therapy
  • Male
  • Middle Aged
  • Platelet Count
  • Prothrombin Time
  • Survival Analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Ultrasonography, Doppler
  • alpha-Fetoproteins / metabolism

Substances

  • Antineoplastic Agents
  • Biomarkers
  • alpha-Fetoproteins